

Supplementary Online Content

Elimova E, Moignard S, Li X, et al. Updating reports of phase 3 clinical trials for cancer. *JAMA Oncol*. Published online February 4, 2021. doi:10.1001/jamaoncol.2020.6968

eTable. Randomized Clinical Trials in Oncology Published Between 1990 and 2010

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Randomized Clinical Trials in Oncology Published Between 1990 and 2010

Covariate	Initial Sample (n=207)	Updated reports (n=41)		Percent of trials updated (20%)
		Initial report	Update	
Journal^a, Number of articles (%)				
JCO	123 (59)	14 (34)	17 (41)	
NEJM	22 (11)	15 (37)	0	
Lancet/ Lancet Oncology	14 (7)	5 (12)	5 (12)	
Annals of Oncology	40 (19)	0 (0)	6 (15)	
Other journal (or update in abstract)	8 (4)	7 (17)	13 (32)	
No. of patients, Median (Range)	429 (100,5187)	633 (156-5187)		
Median follow-up time, months	22 (3, 120)	36 (3, 91)	68 (11-166)	
Tumor site				
breast	87 (42)	27 (66)		31%
lung	109 (53)	11 (27)		10%
prostate	11 (5)	3 (7)		27%
Regimen under evaluation				
chemotherapy	159 (77)	22 (54)		14%
hormonal agent	21 (10)	10 (24)		48%
targeted agent	27 (13)	9 (22)		33%
Disease Setting				
advanced	146 (71)	14 (34)		10%
early	61 (29)	27 (66)		44%
Primary Endpoint^b				
OS	97 (47)	10 (26)		10%
DFS, EFS, RFS	38 (19)	17 (44)		45%
PFS, TTP, TTF	70 (34)	12 (31)		17%
Positive outcome (p≤0.05)	84 (41)	33 (80)		39%
Negative outcome (p>0.05)	123 (59)	8 (20)		7%
Secondary Endpoint				
OS	103 (50)	31 (76)		
DFS, EFS, RFS	8 (4)	6 (15)		
PFS, TTP, TTF	76 (37)	4 (10)		
Other/not specified	20 (10)	0 (0)		

^aOther journals included the index journal JAMA

^b2 trials (2 updated) had other primary endpoints

Note: The positive or negative trials are decided based on adjusted p-values where they are given and the unadjusted p-values are used for trials where no adjustment was made.